Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland

ConclusionsResults suggest that indication development is prioritised according to clinical value and disease prevalence. Countries employ different mechanisms to account for each indication ’s differential benefit, e.g., weighted-average prices (Germany, France, Australia), differential discounts (England, Scotland), clinical restrictions, and MEAs (England, Scotland, Australia, Canada).Value-basedindication-specific pricing can help to align the benefit and price for multi-indication cancer drugs.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research